FRTX Fresh Tracks Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: FRTX

Price (delayed)

$0.86

Market cap

$2.59M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7

Enterprise value

-$8.66M

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative and differentiated prescription therapeutics for debilitating skin diseases with a focus on its lead asset sofpironium ...

Highlights
The debt has plunged by 100% YoY
Fresh Tracks Therapeutics's EPS has soared by 69% YoY and by 42% from the previous quarter
Fresh Tracks Therapeutics's equity has decreased by 44% YoY and by 28% from the previous quarter
The quick ratio has contracted by 31% YoY and by 31% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://brickellbio.com

Key stats

What are the main financial stats of FRTX
Market
Shares outstanding
3.01M
Market cap
$2.59M
Enterprise value
-$8.66M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.22
Price to sales (P/S)
0.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.73
Earnings
Revenue
$5M
EBIT
-$22.63M
EBITDA
-$22.56M
Free cash flow
-$21.6M
Per share
EPS
-$7
Free cash flow per share
-$7.43
Book value per share
$3.91
Revenue per share
$1.72
TBVPS
$4.97
Balance sheet
Total assets
$14.45M
Total liabilities
$3.22M
Debt
$0
Equity
$11.22M
Working capital
$11.05M
Liquidity
Debt to equity
0
Current ratio
4.43
Quick ratio
3.49
Net debt/EBITDA
0.5
Margins
EBITDA margin
-451.5%
Gross margin
100%
Net margin
-453.1%
Operating margin
-465.2%
Efficiency
Return on assets
-108.5%
Return on equity
-133.6%
Return on invested capital
N/A
Return on capital employed
-201.7%
Return on sales
-452.9%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FRTX stock price

How has the Fresh Tracks Therapeutics stock price performed over time
Intraday
-2.44%
1 week
4.88%
1 month
-53.76%
1 year
193.62%
YTD
-42.67%
QTD
-42.67%

Financial performance

How have Fresh Tracks Therapeutics's revenue and profit performed over time
Revenue
$5M
Gross profit
$5M
Operating income
-$23.25M
Net income
-$22.64M
Gross margin
100%
Net margin
-453.1%
The net margin has soared by 96% YoY and by 30% from the previous quarter
FRTX's operating margin has soared by 96% YoY and by 29% from the previous quarter
The operating income has increased by 44% YoY and by 24% QoQ
The net income rose by 44% YoY and by 24% QoQ

Growth

What is Fresh Tracks Therapeutics's growth rate over time

Valuation

What is Fresh Tracks Therapeutics stock price valuation
P/E
N/A
P/B
0.22
P/S
0.5
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
-1.73
Fresh Tracks Therapeutics's EPS has soared by 69% YoY and by 42% from the previous quarter
The price to book (P/B) is 82% lower than the 5-year quarterly average of 1.3 and 79% lower than the last 4 quarters average of 1.1
Fresh Tracks Therapeutics's equity has decreased by 44% YoY and by 28% from the previous quarter
FRTX's P/S is 98% lower than its 5-year quarterly average of 32.3 and 98% lower than its last 4 quarters average of 29.1
The company's revenue rose by 8% QoQ

Efficiency

How efficient is Fresh Tracks Therapeutics business performance
Fresh Tracks Therapeutics's ROS has soared by 96% YoY and by 30% from the previous quarter
The ROE has grown by 19% YoY and by 14% from the previous quarter
The company's return on assets rose by 16% YoY and by 15% QoQ

Dividends

What is FRTX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FRTX.

Financial health

How did Fresh Tracks Therapeutics financials performed over time
Fresh Tracks Therapeutics's total assets has decreased by 40% YoY and by 22% from the previous quarter
The quick ratio has contracted by 31% YoY and by 31% from the previous quarter
The debt is 100% less than the equity
The debt has plunged by 100% YoY
Fresh Tracks Therapeutics's equity has decreased by 44% YoY and by 28% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.